Minerva Neurosciences, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops new therapies to treat central nervous system (CNS) and neuropsychiatric diseases. Minerva Neurosciences serves communities in the United States.

Current Report (Form 8-K | Period ending 2024-12-05)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Minerva Neurosciences (NERV US)

Current Report (Form 8-K | Period ending 2024-12-05)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Annual Report to Security Holders (Form ARS | Period ending 2023-12-31)

Current Report (Form 8-K | Period ending 2024-10-08)

Current Report (Form 8-K | Period ending 2024-09-14)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)